Mylan (NSDQ:MYL) shares fell more than -6% this morning after it posted second quarter results that missed analysts’ sales and earnings estimates.
The generics-maker announced that it would not include any major U.S. product launches in its forecast for the full-year, citing uncertainty in the U.S. regulatory market. Other generic drugmakers, like Teva Pharmaceuticals (NYSE:TEVA), have posted disappointing Q2 results on the heels of regulatory efforts to approve more generic drugs and boost competition.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan tumbles on Q2 miss, lowered outlook appeared first on MassDevice.